Private Equity

Nordson's record earnings reveal the high-tech backbone of premium goods and a resilient, behind-the-scenes investment in the high life.

Beyond the headlines of a $592M debt reduction, McGraw Hill is executing a dual strategy: fortifying its finances to fund a digital and AI-driven future.

As CEO De Lyle Bloomquist announces his retirement, Rayonier Advanced Materials seeks a new leader to steer its ambitious 'BioFuture' strategy amid market volatility.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

Atlantica's latest acquisition is more than just megawatts; it's a calculated move to capture Canada's green energy boom and secure long-term growth.

How a bold $100M pandemic-era investment in a NYC landmark defied market gloom, achieving 100% occupancy and setting a new standard for office resilience.

Beyond the headline, Azul's acquisition of Payara signals a major shift, creating a unified open-source alternative to challenge proprietary Java platforms.

UST's acquisition of Italdesign from Audi Group signals a new era where AI and software are as crucial as chassis and steel in automotive innovation.

Borr Drilling leverages complex debt and equity financing to acquire five premium rigs, a high-stakes bet on a strengthening offshore drilling market.

Value Added Distributors' purchase of a wire harness maker isn't just a deal; it's a strategic play reshaping the landscape for OEM component suppliers.

Unicharm's new water-saving diaper recycling tech isn't just eco-friendly. It's a bold strategic move to dominate the future of sustainable personal care.

A regulatory filing reveals a key investor's move as Alkermes' $2.1B bid for Avadel and its blockbuster narcolepsy drug, LUMRYZ, nears its final act.

The Army is outsourcing pilot training. A new alliance of industry and academia aims to win the bid, blending operational scale with proven teaching excellence.

A $2.4B deal for AI's future. A hedge fund's strategic play. We decode the battle for Alphawave, the company powering the next tech revolution.

A $2.4B semiconductor deal seems distant from medicine, but it's forging the AI hardware backbone for the next generation of precision health.

Bregal Milestone's majority investment in Beyond Now is more than a deal; it’s a bet on how Agentic AI will rewire complex digital supply chains.

With a massive lodge expansion and an all-inclusive dining plan, the cruise line is making a strategic play to dominate the lucrative Alaska land-tour market.

The 2025 proxy season saw record director support as investors prioritized financials, yet dissent over executive pay signals a new battleground.

Balyasny Asset Management's complex derivative stake in JTC plc reveals the hidden strategies shaping a major takeover and the capital flows funding innovation.

With a new patent, this biotech targets the massive orthopedics market. But can its novel fibroblast therapy overcome steep financial and clinical hurdles?